Vaccination against COVID-19 decreases hospitalizations in patients with cirrhosis: Results from a nationwide analysis.
作者信息
Díaz Luis Antonio, Fuentes-López Eduardo, Lazo Mariana, Kamath Patrick S, Arrese Marco, Arab Juan Pablo
机构信息
Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Departamento de Ciencias de la Salud, Carrera de Fonoaudiología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
出版信息
Liver Int. 2022 Apr;42(4):942-944. doi: 10.1111/liv.15193. Epub 2022 Feb 15.
Abstract
摘要
相似文献
1
Vaccination against COVID-19 decreases hospitalizations in patients with cirrhosis: Results from a nationwide analysis.接种新冠疫苗可降低肝硬化患者的住院率：一项全国性分析的结果
Liver Int. 2022 Apr;42(4):942-944. doi: 10.1111/liv.15193. Epub 2022 Feb 15.
2
COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status.失代偿期肝硬化患者的 COVID-19 疫苗：一项回顾性队列研究，评估安全性数据和与未接种状态相关的风险因素。
Infect Dis Poverty. 2022 May 16;11(1):56. doi: 10.1186/s40249-022-00982-0.
3
Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis.BNT162b2 mRNA 疫苗和 mRNA-1273 疫苗与肝硬化患者 COVID-19 感染和住院的关联。
JAMA Intern Med. 2021 Oct 1;181(10):1306-1314. doi: 10.1001/jamainternmed.2021.4325.
4
Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.当在丹麦将第一剂 ChAdOx1 疫苗与随后的 mRNA 疫苗相结合时，针对 SARS-CoV-2 感染、住院和死亡的疫苗有效性：一项全国范围内基于人群的队列研究。
PLoS Med. 2021 Dec 17;18(12):e1003874. doi: 10.1371/journal.pmed.1003874. eCollection 2021 Dec.
5
The vaccine-response in patients with cirrhosis after COVID-19 vaccination: A systematic analysis of 168,245 patients with cirrhosis.新冠病毒疫苗接种后肝硬化患者的疫苗反应：对168245例肝硬化患者的系统分析
J Hepatol. 2023 Oct;79(4):e157-e162. doi: 10.1016/j.jhep.2023.06.011. Epub 2023 Jul 1.
6
Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.肝移植受者和慢性肝病患者接种新冠疫苗后的抗体反应分析。
J Hepatol. 2021 Dec;75(6):1434-1439. doi: 10.1016/j.jhep.2021.08.008. Epub 2021 Aug 26.
7
Coronavirus disease 2019 (COVID-19) vaccination in patients with cirrhosis: Does it work?2019冠状病毒病（COVID-19）在肝硬化患者中的疫苗接种：有效吗？
Hepatol Commun. 2022 Jun;6(6):1502-1503. doi: 10.1002/hep4.1931. Epub 2022 Apr 16.
8
Features of the humoral response to immunization "Gam-COVID-Vac" and in patients with COVID-19.接种“加马列亚”疫苗后体液免疫应答的特点和 COVID-19 患者的特点。
Klin Lab Diagn. 2022 Apr 17;67(4):227-233. doi: 10.51620/0869-2084-2022-67-4-227-233.
9
Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign.主要 COVID-19 疫苗接种周期和加强剂量的效果：意大利全国疫苗接种运动分析。
Eur J Public Health. 2022 Apr 1;32(2):328-330. doi: 10.1093/eurpub/ckab220.
10
Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.单次接种基于 chimpanzee 腺病毒的疫苗可诱导针对 SARS-CoV-2 感染的持续和保护性免疫。
Front Immunol. 2021 Jun 28;12:697074. doi: 10.3389/fimmu.2021.697074. eCollection 2021.
引用本文的文献
1
Efficacy, immunogenicity, and safety of COVID-19 vaccines in individuals with liver cirrhosis: a rapid review and meta-analysis.新冠病毒疫苗在肝硬化患者中的疗效、免疫原性及安全性：一项快速综述与荟萃分析
Clin Exp Vaccine Res. 2024 Apr;13(2):83-90. doi: 10.7774/cevr.2024.13.2.83. Epub 2024 Apr 30.
2
Risk of Severe COVID-19-Related Outcomes among Patients with Cirrhosis: A Population-Based Cohort Study in Canada.肝硬化患者发生严重 COVID-19 相关结局的风险：加拿大基于人群的队列研究。
Viruses. 2024 Feb 24;16(3):351. doi: 10.3390/v16030351.
3
Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis.新冠病毒疫苗在肝硬化患者中的免疫原性：一项荟萃分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2326316. doi: 10.1080/21645515.2024.2326316. Epub 2024 Mar 11.
4
Efficacy, Safety and Immunogenicity of Anti-SARS-CoV-2 Vaccines in Patients with Cirrhosis: A Narrative Review.抗SARS-CoV-2疫苗在肝硬化患者中的疗效、安全性和免疫原性：一项叙述性综述。
Vaccines (Basel). 2023 Feb 16;11(2):452. doi: 10.3390/vaccines11020452.
5
Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.特殊人群 COVID-19 疫苗接种的获益-风险评估。
Vaccine. 2022 Jul 30;40(32):4348-4360. doi: 10.1016/j.vaccine.2022.05.067. Epub 2022 May 27.
本文引用的文献
1
COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence.新型冠状病毒肺炎与间接肝损伤：证据的叙述性综述
J Clin Transl Hepatol. 2021 Oct 28;9(5):760-768. doi: 10.14218/JCTH.2020.00140. Epub 2021 Jun 16.
2
Coordinated cellular and humoral immune responses after two-dose SARS-CoV2 mRNA vaccination in liver transplant recipients.肝移植受者接种两剂 SARS-CoV-2 mRNA 疫苗后协调的细胞和体液免疫应答。
Liver Int. 2022 Jan;42(1):180-186. doi: 10.1111/liv.15089. Epub 2021 Nov 17.
3
Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.肝移植受者和慢性肝病患者接种新冠疫苗后的抗体反应分析。
J Hepatol. 2021 Dec;75(6):1434-1439. doi: 10.1016/j.jhep.2021.08.008. Epub 2021 Aug 26.
4
Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis.BNT162b2 mRNA 疫苗和 mRNA-1273 疫苗与肝硬化患者 COVID-19 感染和住院的关联。
JAMA Intern Med. 2021 Oct 1;181(10):1306-1314. doi: 10.1001/jamainternmed.2021.4325.
5
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients.实体器官移植受者接种三剂mRNA新冠疫苗
N Engl J Med. 2021 Aug 12;385(7):661-662. doi: 10.1056/NEJMc2108861. Epub 2021 Jun 23.
6
An Uncertain Public - Encouraging Acceptance of Covid-19 Vaccines.一个不确定的公众——鼓励对新冠疫苗的接受
N Engl J Med. 2021 Apr 22;384(16):1483-1487. doi: 10.1056/NEJMp2100351. Epub 2021 Mar 3.
7
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.BNT162b2 mRNA 新冠病毒疫苗在全国大规模疫苗接种环境中的效果。
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
8
COVID-19 risk, disparities and outcomes in patients with chronic liver disease in the United States.美国慢性肝病患者的新冠病毒病风险、差异及转归
EClinicalMedicine. 2021 Jan;31:100688. doi: 10.1016/j.eclinm.2020.100688. Epub 2020 Dec 22.
9
SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question.肝病患者的新冠病毒疫苗接种：应对下一个重大问题。
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):156-158. doi: 10.1016/S2468-1253(21)00008-X. Epub 2021 Jan 11.
10
Beyond Politics - Promoting Covid-19 Vaccination in the United States.超越政治——在美国推广新冠疫苗接种
N Engl J Med. 2021 Feb 18;384(7):e23. doi: 10.1056/NEJMms2033790. Epub 2021 Jan 6.
Zotero 插件